Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2009 1
2010 3
2012 1
2013 1
2014 3
2015 5
2016 2
2017 2
2019 2
2020 2
2021 4
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Signs and symptoms of COVID-19 in patients with multiple sclerosis.
Schiavetti I, Carmisciano L, Ponzano M, Cordioli C, Cocco E, Marfia GA, Inglese M, Filippi M, Radaelli M, Bergamaschi R, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Scandellari C, Cavalla P, Pesci I, Confalonieri P, Perini P, Trojano M, Lanzillo R, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 Study Group. Schiavetti I, et al. Eur J Neurol. 2022 Dec;29(12):3728-3736. doi: 10.1111/ene.15554. Epub 2022 Sep 23. Eur J Neurol. 2022. PMID: 36086905 Free PMC article.
Biological monitoring of IFN-β therapy in Multiple Sclerosis.
Bertolotto A, Granieri L, Marnetto F, Valentino P, Sala A, Capobianco M, Malucchi S, Di Sapio A, Malentacchi M, Matta M, Caldano M. Bertolotto A, et al. Among authors: malentacchi m. Cytokine Growth Factor Rev. 2015 Apr;26(2):241-8. doi: 10.1016/j.cytogfr.2014.12.002. Epub 2014 Dec 24. Cytokine Growth Factor Rev. 2015. PMID: 25596967 Review.
Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study.
Bruschi N, Malentacchi M, Malucchi S, Sperli F, Martire S, Sala A, Valentino P, Bertolotto A, Pautasso M, Capobianco MA. Bruschi N, et al. Among authors: malentacchi m. Neurol Ther. 2023 Aug;12(4):1375-1383. doi: 10.1007/s40120-023-00481-w. Epub 2023 May 11. Neurol Ther. 2023. PMID: 37166677 Free PMC article.
An assessment of Hispanic health status.
Malentacchi ME, Cruz N, Wolf S. Malentacchi ME, et al. Conn Med. 2004 Jan;68(1):37-41. Conn Med. 2004. PMID: 14752915 Review.
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context.
Sormani MP, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; MuSC-19 Study Group. Sormani MP, et al. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 9;9(1):e1105. doi: 10.1212/NXI.0000000000001105. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34753829 Free PMC article.
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab.
Sottini A, Quaresima V, Barbaro M, Moiola L, Filippi M, Malentacchi M, Capobianco M, Puthenparampil M, Gallo P, Cocco E, Frau J, Zaffaroni M, Guaschino C, Stampatori C, Mancinelli C, Brambilla L, Clerici VT, Vianello M, Vitetta F, Ferraro D, Rosettani P, Danni MC, Conti M, Grimoldi M, Capra R, Imberti L. Sottini A, et al. Among authors: malentacchi m. J Neuroimmunol. 2023 Sep 15;382:578170. doi: 10.1016/j.jneuroim.2023.578170. Epub 2023 Aug 7. J Neuroimmunol. 2023. PMID: 37579546 Free article.
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C, Bovis F, Novi G, Capobianco M, Lanzillo R, Frau J, Repice AM, Hakiki B, Realmuto S, Bonavita S, Curti E, Brambilla L, Mataluni G, Cavalla P, Di Sapio A, Signoriello E, Barone S, Maniscalco GT, Maietta I, Maraffi I, Boffa G, Malucchi S, Nozzolillo A, Coghe G, Mechi C, Salemi G, Gallo A, Sacco R, Cellerino M, Malentacchi M, De Angelis M, Lorefice L, Magnani E, Prestipino E, Sperli F, Brescia Morra V, Fenu G, Barilaro A, Abbadessa G, Signori A, Granella F, Amato MP, Uccelli A, Gobbi C, Sormani MP. Zecca C, et al. Among authors: malentacchi m. Mult Scler. 2020 Oct;26(12):1519-1531. doi: 10.1177/1352458519872889. Epub 2019 Oct 1. Mult Scler. 2020. PMID: 31573386
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study.
Sormani MP, Schiavetti I, Landi D, Carmisciano L, De Rossi N, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Brescia Morra V, Trojano M, Tedeschi G, Comi G, Battaglia MA, Patti F, Fragoso YD, Sen S, Siva A, Furlan R, Salvetti M; MuSC-19 Study Group. Sormani MP, et al. Mult Scler. 2022 Jun;28(7):1034-1040. doi: 10.1177/13524585211035318. Epub 2021 Jul 30. Mult Scler. 2022. PMID: 34328824
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis.
Bergamaschi R, Ponzano M, Schiavetti I, Carmisciano L, Cordioli C, Filippi M, Radaelli M, Immovilli P, Capobianco M, De Rossi N, Brichetto G, Cocco E, Scandellari C, Cavalla P, Pesci I, Zito A, Confalonieri P, Marfia GA, Perini P, Inglese M, Trojano M, Brescia Morra V, Pisoni E, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Sormani MP; MuSC-19 study group. Bergamaschi R, et al. Eur J Neurol. 2022 Feb;29(2):535-542. doi: 10.1111/ene.15167. Epub 2021 Nov 15. Eur J Neurol. 2022. PMID: 34735749 Free PMC article.
24 results